KURA ONCOLOGY, INC.
KURA US50127T1097
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -59% | -16% | 19% | -43% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Powl Brian T. CCO |
8.94 USD |
8,891 Sold |
79,505 USD |
27/09/2025 | 29/09/2025 |
| Wilson Troy Edward CEO |
8.94 USD |
36,615 Sold |
327,419 USD |
27/09/2025 | 29/09/2025 |
| Ford Kathleen COO |
8.94 USD |
6,892 Sold |
61,630 USD |
27/09/2025 | 29/09/2025 |
| Leoni Mollie SR OFF |
8.94 USD |
12,314 Sold |
110,114 USD |
27/09/2025 | 29/09/2025 |
| Doyle Thomas James VP |
8.94 USD |
4,541 Sold |
40,607 USD |
27/09/2025 | 29/09/2025 |
| Bair Teresa Brophy CLO |
8.94 USD |
8,805 Sold |
78,736 USD |
27/09/2025 | 29/09/2025 |
| Wilson Troy Edward CEO |
8.20 USD |
50,000 Bought |
410,145 USD |
08/09/2025 | 08/09/2025 |
| Wilson Troy Edward CEO |
6.64 USD |
13,494 Bought |
89,623 USD |
12/08/2025 | 13/08/2025 |
| Wilson Troy Edward CEO |
5.85 USD |
36,506 Bought |
213,578 USD |
12/08/2025 | 12/08/2025 |
| Ford Kathleen COO |
6.28 USD |
1,558 Sold |
9,777 USD |
19/05/2025 | 19/05/2025 |